Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZMSPF)

• Drug Name: Bicalutamide Drug Info
• Synonyms: Casodex; Cosudex; Propanamide; Raffolutil; Astra brand of bicalutamide; AstraZeneca brand of bicalutamide; Zeneca brand of bicalutamide; Calutide (TN); Casodex (TN); Cosudex (TN); KS-1161; Kalumid (TN); Bicalutamide [USAN:INN:BAN]; Bicalutamide (JAN/USP/INN); Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Approved	[1]
Castration-resistant prostate carcinoma		Investigative	[2]
Metastatic prostate carcinoma		Investigative	[2]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 2375
  ChEBI ID: CHEBI:91617
  CAS Number: CAS 90357-06-5
  TTD Drug ID: DMZMSPF
  VARIDT Drug ID: DR00795
  INTEDE Drug ID: DR0210
  ACDINA Drug ID: D00069

Molecule-Related Drug Atlas

Drug(s) Targeting Androgen receptor (AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[10]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[11]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[12]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[13]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[14]
Fludrocortisone	DMUDIR8	Addison disease	5A74.0	Approved	[15]
ARN-509	DMT81LZ	Acute myeloid leukaemia	2A60	Approved	[16]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[17]
Nandrolone	DMFWKG1	Osteoporosis	FB83.0	Approved	[18]
Fluoxymesterone	DMUHCF1	Breast cancer	2C60-2C65	Approved	[19]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[45]
Nilutamide	DMFN07X	Prostate cancer	2C82.0	Approved	[45]
Hydroxyflutamide	DMGIZF5	Prostate cancer	2C82.0	Approved	[45]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[46]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[47]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[48]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[49]
Selenium	DM25CGV	N. A.	N. A.	Approved	[50]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[51]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[20]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[21]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[22]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[23]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[22]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[22]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[24]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[22]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[25]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[26]

Drug(s) Transported By Breast cancer resistance protein (ABCG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[27]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[28]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[29]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[30]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[31]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[32]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[33]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[32]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[34]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[35]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[36]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[37]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[38]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[39]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[40]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[41]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[42]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[43]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[37]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[44]

Drug(s) Affected By Telomerase reverse transcriptase (TERT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[53]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[54]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[55]
Selenium	DM25CGV	N. A.	N. A.	Approved	[56]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[58]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[59]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[60]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[61]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[62]

Drug(s) Affected By Neuropilin-1 (NRP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[63]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[64]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[65]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[72]

Drug(s) Affected By Calmegin (CLGN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[73]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[73]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[75]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[77]

Drug(s) Affected By Baculoviral IAP repeat-containing protein 5 (BIRC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[78]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[79]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[80]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[81]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[82]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[83]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[84]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[85]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[86]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[87]

Drug(s) Affected By Protein regulator of cytokinesis 1 (PRC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[63]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[88]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[90]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[92]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[92]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]

Drug(s) Affected By Mitotic checkpoint serine/threonine-protein kinase BUB1 beta (BUB1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[93]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[78]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[95]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By H/ACA ribonucleoprotein complex subunit DKC1 (DKC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[97]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[96]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[101]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[102]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[103]
DNCB	DMDTVYC	Immune System disease	4A01-4B41	Phase 2	[104]

Drug(s) Affected By Nebulette (NEBL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[68]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[106]
Melphalan	DMOLNHF	Hematologic disease	3C0Z	Approved	[107]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[108]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[110]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[68]

Drug(s) Affected By Kinesin-like protein KIF20A (KIF20A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[112]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[113]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By Anterior gradient protein 2 homolog (AGR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[108]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[115]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[116]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]

Drug(s) Affected By Myc proto-oncogene protein (MYC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[117]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[118]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[119]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[120]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[55]
Selenium	DM25CGV	N. A.	N. A.	Approved	[121]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[122]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[123]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[124]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[125]

Drug(s) Affected By Pro-glucagon (GCG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[126]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[127]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[128]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[129]
Gatifloxacin	DMSL679	Acute gonococcal cervicitis		Approved	[130]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[131]
geraniol	DMS3CBD	Discovery agent	N.A.	Investigative	[132]

Drug(s) Affected By Thymidine kinase, cytosolic (TK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[133]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[134]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[135]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[136]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[137]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[138]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[139]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[140]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[125]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[141]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[142]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[143]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[144]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[145]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[146]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[147]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[148]

Drug(s) Affected By Cholinesterase (BCHE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[149]
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[150]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[151]
Rivastigmine	DMG629M	Alzheimer disease	8A20	Approved	[152]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[153]
Succinylcholine	DM2ET1M	Plasma cell myeloma	2A83.1	Approved	[154]
Ethopropazine	DM0N3L7	Parkinson disease	8A00.0	Approved	[150]
Dimenhydrinate	DM264B3	Meniere disease	AB31.0	Approved	[155]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[156]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[155]

Drug(s) Affected By Cyclin-dependent kinase 1 (CDK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[93]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[157]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[78]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Selenium	DM25CGV	N. A.	N. A.	Approved	[121]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[82]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[158]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[64]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[159]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[160]

Drug(s) Affected By Prostate-specific antigen (KLK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[63]
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[161]
Selenium	DM25CGV	N. A.	N. A.	Approved	[50]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[162]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[163]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[164]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[165]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[166]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]

Drug(s) Affected By Amino acid transporter heavy chain SLC3A2 (SLC3A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[83]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[168]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[169]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[170]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[169]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[171]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[92]

Drug(s) Affected By Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[73]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[172]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[173]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[174]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[175]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]

Drug(s) Affected By Proliferating cell nuclear antigen (PCNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[119]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[177]
Selenium	DM25CGV	N. A.	N. A.	Approved	[121]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[178]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[179]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[180]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[64]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[159]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[181]

Drug(s) Affected By Prostatic acid phosphatase (ACP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[182]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[171]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[183]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[184]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[185]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[186]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]

Drug(s) Affected By Cyclic AMP-dependent transcription factor ATF-3 (ATF3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[187]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[135]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[83]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[188]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[159]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[189]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[190]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[170]

Drug(s) Affected By C-X-C motif chemokine 3 (CXCL3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[191]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[192]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[73]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[193]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[194]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[195]

Drug(s) Affected By Kallikrein-2 (KLK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[196]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[197]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[198]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Dutasteride	DMQ4TJK	Benign prostatic hyperplasia	GA90	Approved	[200]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[201]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[202]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[203]

Drug(s) Affected By Lamin-B1 (LMNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[204]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[205]
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[206]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[207]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[208]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]

Drug(s) Affected By Midkine (MDK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[209]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[210]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[211]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[195]
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[212]

Drug(s) Affected By Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[187]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[118]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[213]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[214]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[83]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[215]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[216]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[217]
Furazolidone	DM3P6V7	Diarrhea	ME05.1	Approved	[218]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[219]

Drug(s) Affected By Protein S100-P (S100P)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[220]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[135]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[221]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[222]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[223]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[172]
Adenosine triphosphate	DM79F6G	Malnutrition	5B50-5B71	Approved	[224]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]

Drug(s) Affected By Ribonucleoside-diphosphate reductase subunit M2 (RRM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[225]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[93]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[207]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[226]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[227]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]

Drug(s) Affected By Stress-induced-phosphoprotein 1 (STIP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[228]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[229]
Haloperidol	DM96SE0	Delirium		Approved	[230]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Tubocurarine	DMBZIVP	Anaesthesia	9A78.6	Approved	[231]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[230]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[230]
Mecamylamine	DMGQFYB	Essential hypertension	BA00	Approved	[231]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[232]

Drug(s) Affected By Cyclin-dependent kinases regulatory subunit 2 (CKS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[233]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[227]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[234]

Drug(s) Affected By Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA (MAN1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[55]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[210]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[236]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[237]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[238]

Drug(s) Affected By Glypican-1 (GPC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[239]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[234]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[110]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[240]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[241]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1 (CDKN1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[242]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[243]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[244]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[79]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[245]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[135]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[82]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[246]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[247]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[113]

Drug(s) Affected By Cyclin-dependent kinase 4 inhibitor C (CDKN2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[248]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[233]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[226]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]

Drug(s) Affected By Ran-specific GTPase-activating protein (RANBP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[192]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[227]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[249]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[249]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]

Drug(s) Affected By Proliferation marker protein Ki-67 (MKI67)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[250]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[251]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Remdesivir	DMBFZ6L	Coronavirus Disease 2019 (COVID-19)	1D6Y	Approved	[252]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[233]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[253]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[254]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[171]

Drug(s) Affected By DNA replication licensing factor MCM2 (MCM2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[255]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[256]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[257]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]

Drug(s) Affected By Aldehyde dehydrogenase family 3 member A2 (ALDH3A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[90]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[190]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[185]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[258]

Drug(s) Affected By Serine/threonine-protein kinase Nek2 (NEK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[78]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[177]
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]

Drug(s) Affected By Thyroxine 5-deiodinase (DIO3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[259]
Vemurafenib	DM62UG5	Melanoma	2C30	Approved	[260]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[173]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ergocalciferol	DMHO0AR	Hypoparathyroidism	5A50	Approved	[261]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[259]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[261]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[259]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[262]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[259]

Drug(s) Affected By Neutrophil gelatinase-associated lipocalin (LCN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[208]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[208]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[263]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[172]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[193]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[185]
Gentamicin	DMKINJO	Bacteremia	1A73	Approved	[264]

Drug(s) Affected By Cell division cycle protein 20 homolog (CDC20)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[93]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[78]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[265]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[266]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]

Drug(s) Affected By Mitotic spindle assembly checkpoint protein MAD2A (MAD2L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[93]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[78]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[159]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[221]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[267]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]

Drug(s) Affected By Sequestosome-1 (SQSTM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[268]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[269]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[270]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[271]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[272]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[83]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[64]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[273]

Drug(s) Affected By Transmembrane glycoprotein NMB (GPNMB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[226]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[92]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[92]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[274]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[185]

Drug(s) Affected By 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase (EBP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[275]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[227]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[185]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]

Drug(s) Affected By Quinone oxidoreductase PIG3 (TP53I3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[81]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[64]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[276]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[277]
Amifostine	DM5FL14	Mucositis	CA00	Approved	[278]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[279]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[280]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[92]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[92]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[92]

Drug(s) Affected By Retinoic acid-induced protein 3 (GPRC5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[281]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[282]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[172]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[279]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[97]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[185]

Drug(s) Affected By Fibroblast growth factor 13 (FGF13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[283]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[202]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[284]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[285]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[286]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[131]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[287]

Drug(s) Affected By Lymphokine-activated killer T-cell-originated protein kinase (PBK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[288]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]

Drug(s) Affected By Tribbles homolog 3 (TRIB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[187]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[190]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[289]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[169]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[170]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[290]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[169]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[172]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[291]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[171]

Drug(s) Affected By BRCA1-associated RING domain protein 1 (BARD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[249]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[274]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[292]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[293]

Drug(s) Affected By Homeobox protein Nkx-3.1 (NKX3-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[52]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[294]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[171]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[198]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[9]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[295]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[296]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[297]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[298]

Drug(s) Affected By GTP-binding protein 2 (GTPBP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[192]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[299]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[172]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[300]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[301]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[236]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[237]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[76]

Drug(s) Affected By Nucleolar and spindle-associated protein 1 (NUSAP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[90]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[227]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]

Drug(s) Affected By Peroxisomal trans-2-enoyl-CoA reductase (PECR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[125]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[279]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[72]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[302]

Drug(s) Affected By Protein Niban 1 (NIBAN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[303]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[172]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[304]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[184]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[305]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[185]

Drug(s) Affected By Rac GTPase-activating protein 1 (RACGAP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[112]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[159]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[75]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[292]

Drug(s) Affected By E3 ubiquitin-protein ligase CCNB1IP1 (CCNB1IP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[171]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[210]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[306]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[306]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[307]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[308]

Drug(s) Affected By Peptidyl-prolyl cis-trans isomerase FKBP11 (FKBP11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[90]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[309]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[307]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[310]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[198]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[68]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[311]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[131]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[287]

Drug(s) Affected By DnaJ homolog subfamily B member 9 (DNAJB9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[187]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[312]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[291]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[187]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[92]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[92]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[304]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[313]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[92]

Drug(s) Affected By Alpha-methylacyl-CoA racemase (AMACR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[125]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[314]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[226]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[279]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[315]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]

Drug(s) Affected By E3 ISG15--protein ligase HERC5 (HERC5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[73]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[172]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Azathioprine	DMMZSXQ	Lupus nephritis	4A40.0Y	Approved	[73]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[73]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[73]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[306]

Drug(s) Affected By Cell cycle progression protein 1 (CCPG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[283]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[316]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[57]
Bortezomib	DMNO38U	Leukemia		Approved	[316]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]

Drug(s) Affected By Targeting protein for Xklp2 (TPX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[105]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[292]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[185]

Drug(s) Affected By Cystine/glutamate transporter (SLC7A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[317]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[318]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[319]
Lumiracoxib	DM1S4AG	Chronic renal failure	GB61.Z	Approved	[318]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[318]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[73]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[320]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[169]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[318]

Drug(s) Affected By Lysosome-associated membrane glycoprotein 3 (LAMP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[184]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[305]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[309]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[301]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[301]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[108]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[110]

Drug(s) Affected By Hypoxia up-regulated protein 1 (HYOU1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[304]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[236]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[237]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[321]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[322]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[198]

Drug(s) Affected By Electrogenic sodium bicarbonate cotransporter 1 (SLC4A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium bicarbonate	DMMU6BJ	Metabolic acidosis	5C73	Approved	[323]
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[313]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[185]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[324]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[258]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]

Drug(s) Affected By Kunitz-type protease inhibitor 2 (SPINT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[265]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[90]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[227]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[193]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[325]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[326]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[306]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[306]

Drug(s) Affected By Neprilysin (MME)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[327]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[171]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[328]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[329]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[330]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[237]

Drug(s) Affected By Retinoic acid receptor beta (RARB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[331]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[221]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[332]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[333]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[305]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[334]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[335]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[331]

Drug(s) Affected By S-adenosylmethionine decarboxylase proenzyme (AMD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[207]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[171]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Indomethacin	DMSC4A7	Bursitis		Approved	[336]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[258]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[337]

Drug(s) Affected By CD9 antigen (CD9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[338]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[339]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Bortezomib	DMNO38U	Leukemia		Approved	[300]

Drug(s) Affected By Long-chain-fatty-acid--CoA ligase 1 (ACSL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[283]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[137]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[340]
Tolcapone	DM8MNVO	Parkinson disease	8A00.0	Approved	[341]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[92]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[92]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[92]

Drug(s) Affected By Histone H2B type 1-B (H2BC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[274]
Dasatinib	DMJV2EK	Blast phase chronic myelogenous leukemia, BCR-ABL1 positive		Approved	[342]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[236]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[96]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[110]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[103]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[131]

Drug(s) Affected By Lipopolysaccharide-responsive and beige-like anchor protein (LRBA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[283]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[207]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[108]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[258]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[343]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[344]

Drug(s) Affected By Synaptosomal-associated protein 25 (SNAP25)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[177]
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[71]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[345]
Heroin diacetylmorphine	DMDBWHY	Neurological disorder	6B60	Approved	[346]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[185]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[108]

Drug(s) Affected By Sorbitol dehydrogenase (SORD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorbitol	DMAN0DE	Constipation	DD91.1	Approved	[347]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[237]
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[153]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[198]

Drug(s) Affected By Rod outer segment membrane protein 1 (ROM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[68]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[108]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[96]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[348]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[307]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[287]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[349]

Drug(s) Affected By BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[265]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[159]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Acetic Acid, Glacial	DM4SJ5Y	infection in the ear canal	AA0Y	Approved	[170]
Quinolones	DM5GVHU	Bacterial infection	1A00-1C4Z	Approved	[350]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[351]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[352]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[279]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[92]

Drug(s) Affected By Cyclin-G2 (CCNG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[353]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[169]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[353]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[90]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[92]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[92]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[210]

Drug(s) Affected By Unconventional myosin-VI (MYO6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[354]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[77]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[184]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[108]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[110]

Drug(s) Affected By Retinoblastoma-associated protein (RB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[355]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[356]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[357]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[245]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[265]
Trametinib	DM2JGQ3	Melanoma	2C30	Approved	[123]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[358]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[359]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[360]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[160]

Drug(s) Affected By Arginase-1 (ARG1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[192]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[89]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[172]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Cholecalciferol	DMGU74E	Adult acute monocytic leukemia		Approved	[361]

Drug(s) Affected By Arginase-2, mitochondrial (ARG2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[338]
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[172]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[304]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[362]

Drug(s) Affected By Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 2 (ASAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[363]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[237]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[76]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[321]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[307]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[364]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[365]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[365]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[366]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[364]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[365]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[367]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[364]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[368]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[364]

Drug(s) Affected By Low-density lipoprotein receptor (LDLR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Levonorgestrel	DM1DP7T	Atypical endometrial hyperplasia		Approved	[369]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[135]
Desogestrel	DM27U4Y	Contraception	QA21	Approved	[369]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[370]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[371]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[137]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[190]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[273]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[372]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[373]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[374]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[375]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[376]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[377]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[378]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[379]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[380]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[381]

Drug(s) Affected By Insulin-like growth factor I (IGF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dantrolene	DM1D8XY	Hyperthermia	MG26	Approved	[382]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[383]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[178]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[384]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[208]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[208]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[90]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[385]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[171]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[386]

Drug(s) Affected By Beta-2 adrenergic receptor (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[387]
Bambuterol	DMKLSHF	Asthma	CA23	Approved	[388]
Terbutaline	DMD4381	Asthma	CA23	Approved	[389]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[390]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[391]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[192]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[392]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[393]
Ergotidine	DM78IME	Osteoarthritis	FA00-FA05	Approved	[394]

Drug(s) Affected By Beta-microseminoprotein (MSMB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[395]
Hydroxyflutamide	DMGIZF5	Prostate cancer	2C82.0	Approved	[396]
Enzalutamide	DMGL19D	Prostate cancer	2C82.0	Approved	[397]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[398]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[399]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[96]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[110]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[400]

Drug(s) Affected By Apoptosis regulator Bcl-2 (BCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[401]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[402]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[403]
Gemcitabine	DMSE3I7	Anterior urethra cancer		Approved	[404]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[153]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[405]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[406]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[407]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[408]

Drug(s) Affected By Prolactin-inducible protein (PIP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydroxyflutamide	DMGIZF5	Prostate cancer	2C82.0	Approved	[409]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[409]
Genistein	DM0JETC	Menopause symptom	GA30.0	Phase 2/3	[410]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[131]
acetaldehyde	DMJFKG4	Discovery agent	N.A.	Investigative	[411]

Drug(s) Affected By Cadherin-1 (CDH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[331]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[412]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[413]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[414]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[415]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[416]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Polyethylene glycol	DM4I1JP	Constipation	DD91.1	Approved	[417]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]

Drug(s) Affected By Lysosome-associated membrane glycoprotein 2 (LAMP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[248]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[110]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[418]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[419]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[310]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[68]
Rigosertib	DMOSTXF	Myelodysplastic syndrome	2A37	Phase 3	[420]

Drug(s) Affected By G2/mitotic-specific cyclin-B1 (CCNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[93]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[157]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[244]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Selenium	DM25CGV	N. A.	N. A.	Approved	[121]
Etretinate	DM2CZFA	Keratosis	ED56	Approved	[82]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[247]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[421]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[83]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]

Drug(s) Affected By Insulin-like growth factor-binding protein 3 (IGFBP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[283]
Selenium	DM25CGV	N. A.	N. A.	Approved	[422]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[282]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[384]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[208]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[229]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[68]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[423]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[386]

Drug(s) Affected By Insulin-like growth factor-binding protein 2 (IGFBP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[281]
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[190]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[207]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[424]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[386]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[184]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]

Drug(s) Affected By Cyclin-A2 (CCNA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[425]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[157]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[119]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[135]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[179]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[358]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[94]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[159]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[426]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[427]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[428]
Methysergide	DM1EF73	Migraine	8A80	Approved	[367]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[429]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[192]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[367]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[137]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[430]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[431]

Drug(s) Affected By G1/S-specific cyclin-D1 (CCND1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[432]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[433]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[408]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[434]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[435]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[245]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[436]
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[122]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[437]

Drug(s) Affected By Retinoic acid receptor RXR-beta (RXRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[438]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[70]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[234]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[439]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[440]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[441]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[442]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[441]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[443]

Drug(s) Affected By Coatomer subunit beta' (COPB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[112]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[96]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[444]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[227]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[184]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[236]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[112]
Afimoxifene	DMFORDT	Breast cancer	2C60-2C65	Phase 2	[112]

Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[356]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[435]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[246]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[445]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[446]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[447]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[448]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[449]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[450]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[451]

Drug(s) Affected By ATP synthase subunit e, mitochondrial (ATP5ME)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[177]
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[452]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[90]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[315]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Indomethacin	DMSC4A7	Bursitis		Approved	[336]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[453]

Drug(s) Affected By Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN (PTEN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[146]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[283]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[454]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[125]
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[455]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[217]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[456]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[457]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[279]

Drug(s) Affected By 26S proteasome complex subunit SEM1 (SEM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[283]
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[307]
phorbol 12-myristate 13-acetate	DMJWD62	Acute myeloid leukaemia	2A60	Phase 2	[458]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[287]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[459]
AHPN	DM8G6O4	Discovery agent	N.A.	Investigative	[460]
chloropicrin	DMSGBQA	Discovery agent	N.A.	Investigative	[461]

Drug(s) Affected By Thymosin beta-4 (TMSB4X)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[208]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[299]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[462]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[463]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[195]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[464]
Indomethacin	DMSC4A7	Bursitis		Approved	[465]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[466]

Drug(s) Affected By Apoptosis regulator BAX (BAX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[401]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[467]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[176]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[405]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[331]
Leuprorelin acetate	DM15HAT	Prostate cancer	2C82.0	Approved	[468]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[245]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[265]
Meloxicam	DM2AR7L	Arthritis	FA20	Approved	[180]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[247]

Drug(s) Affected By Bcl-2-like protein 1 (BCL2L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[146]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[469]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[81]
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[470]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[64]
Dactinomycin	DM2YGNW	Adult kidney Wilms tumor		Approved	[471]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[472]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[255]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[377]

Drug(s) Affected By Peptidyl-prolyl cis-trans isomerase FKBP5 (FKBP5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[207]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[312]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[473]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[474]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[234]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[475]

Drug(s) Affected By Angio-associated migratory cell protein (AAMP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[167]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[297]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[476]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]
Tocopherol	DMBIJZ6	N. A.	N. A.	Phase 2	[167]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[477]

Drug(s) Affected By Translocating chain-associated membrane protein 1 (TRAM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[478]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[241]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[198]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[479]
THAPSIGARGIN	DMDMQIE	N. A.	N. A.	Preclinical	[480]

Drug(s) Affected By Cytochrome P450 1B1 (CYP1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[373]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[135]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[481]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[321]
Estrone	DM5T6US	Acne vulgaris	ED80	Approved	[482]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[483]
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[484]
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[485]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[486]
Pantothenic acid	DM091H2	Vitamin deficiency	5B55-5B71	Approved	[487]

Drug(s) Affected By Phosphatidate cytidylyltransferase, mitochondrial (TAMM41)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[453]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[488]

Drug(s) Affected By Cell division control protein 6 homolog (CDC6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[93]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[113]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[159]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[221]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[66]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[207]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[489]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[91]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[91]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]

Drug(s) Affected By Cytochrome c oxidase assembly factor 1 homolog (COA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[490]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[306]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[306]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[491]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[241]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[325]
TAK-243	DM4GKV2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[492]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[131]

Drug(s) Affected By Ankyrin repeat and IBR domain-containing protein 1 (ANKIB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[67]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[90]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[258]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[493]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]
PMID28870136-Compound-52	DMFDERP	N. A.	N. A.	Patented	[251]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[251]

Drug(s) Affected By Methyl-CpG-binding domain protein 2 (MBD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[494]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[495]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[496]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[497]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[498]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[109]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[499]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[111]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[500]

Drug(s) Affected By Beta-1,4-galactosyltransferase 6 (B4GALT6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[69]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[210]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[98]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Bortezomib	DMNO38U	Leukemia		Approved	[300]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[258]
Trichostatin A	DM9C8NX	Solid tumour/cancer	2A00-2F9Z	Investigative	[313]

Drug(s) Affected By BTB/POZ domain-containing protein 3 (BTBD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[114]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[501]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[210]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[235]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[100]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[199]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[490]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[502]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[503]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[310]

Drug(s) Affected By Proliferation-associated protein 2G4 (PA2G4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[177]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[57]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[504]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[505]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[210]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[99]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[395]
Ampicillin	DMHWE7P	Acute epiglottitis		Approved	[57]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[297]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[108]

Drug(s) Affected By Neurotensin/neuromedin N (NTS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[506]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[226]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[116]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[76]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[184]
Azacitidine	DMTA5OE	Acute myelogenous leukaemia	2A41	Approved	[507]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[508]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[310]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[116]
phorbol 12-myristate 13-acetate	DMJWD62	Acute myeloid leukaemia	2A60	Phase 2	[506]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Antagonist	[3]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[4]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
26S proteasome complex subunit SEM1 (SEM1)	OTASLBM1	SEM1_HUMAN	Gene/Protein Processing	[6]
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase (EBP)	OTSMGKXQ	EBP_HUMAN	Gene/Protein Processing	[7]
Aldehyde dehydrogenase family 3 member A2 (ALDH3A2)	OT714BUO	AL3A2_HUMAN	Gene/Protein Processing	[7]
Alpha-methylacyl-CoA racemase (AMACR)	OTUU22PK	AMACR_HUMAN	Gene/Protein Processing	[7]
Amino acid transporter heavy chain SLC3A2 (SLC3A2)	OTBR33M9	4F2_HUMAN	Gene/Protein Processing	[7]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Drug Response	[8]
Angio-associated migratory cell protein (AAMP)	OTZXBSS4	AAMP_HUMAN	Gene/Protein Processing	[6]
Ankyrin repeat and IBR domain-containing protein 1 (ANKIB1)	OTGKB7Y2	AKIB1_HUMAN	Gene/Protein Processing	[6]
Anterior gradient protein 2 homolog (AGR2)	OTRRZT7W	AGR2_HUMAN	Gene/Protein Processing	[7]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[9]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2863).
• [2] Bicalutamide FDA Label
• [3] Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11.
• [4] Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11.
• [5] Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78.
• [6] Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen. Cancer Genet Cytogenet. 2006 Apr 15;166(2):130-8. doi: 10.1016/j.cancergencyto.2005.09.012.
• [7] Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol. 2005 Jan;57(1):83-92.
• [8] Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate. 2005 Nov 1;65(3):268-75. doi: 10.1002/pros.20282.
• [9] Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12.
• [10] Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87.
• [11] Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [13] Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.
• [14] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [15] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [16] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [17] CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22.
• [18] Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4.
• [19] An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73.
• [20] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [21] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [22] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [23] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [24] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [25] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [26] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [27] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [28] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [29] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [30] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [31] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [32] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [33] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [34] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [35] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [36] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [37] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [38] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [39] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [40] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [41] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [42] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [43] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [44] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [45] TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer. Toxicol Appl Pharmacol. 2016 Sep 15;307:91-101. doi: 10.1016/j.taap.2016.07.018. Epub 2016 Jul 27.
• [46] Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015 Jul 13;43(12):5880-97. doi: 10.1093/nar/gkv262. Epub 2015 Apr 23.
• [47] Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7. J Steroid Biochem Mol Biol. 2002 Jan;80(1):61-70. doi: 10.1016/s0960-0760(01)00173-x.
• [48] Identifying environmental chemicals as agonists of the androgen receptor by using a quantitative high-throughput screening platform. Toxicology. 2017 Jun 15;385:48-58. doi: 10.1016/j.tox.2017.05.001. Epub 2017 May 4.
• [49] Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
• [50] Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res. 2004 Jan 1;64(1):19-22. doi: 10.1158/0008-5472.can-03-2789.
• [51] Comparison of the Hershberger assay and androgen receptor binding assay of twelve chemicals. Toxicology. 2004 Feb 15;195(2-3):177-86. doi: 10.1016/j.tox.2003.09.012.
• [52] Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001 Mar;22(3):409-14. doi: 10.1093/carcin/22.3.409.
• [53] Effect of ellagic acid on the expression of human telomerase reverse transcriptase (hTERT) alpha+beta+ transcript in estrogen receptor-positive MCF-7 breast cancer cells. Clin Biochem. 2009 Sep;42(13-14):1358-62. doi: 10.1016/j.clinbiochem.2009.05.017. Epub 2009 Jun 6.
• [54] Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res. 2006 Sep-Oct;26(5A):3387-91.
• [55] Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
• [56] Inhibitory effects of selenium on telomerase activity and hTERT expression in cadmium-transformed 16HBE cells. Biomed Environ Sci. 2007 Aug;20(4):307-12.
• [57] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [58] Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. BMC Cancer. 2010 Jul 22;10:390. doi: 10.1186/1471-2407-10-390.
• [59] Analysis of telomerase activity and RNA expression in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid. Pediatr Blood Cancer. 2006 Apr;46(4):506-11. doi: 10.1002/pbc.20392.
• [60] Characterization of the functional and growth properties of long-term cell cultures established from a human somatostatinoma. Endocr Relat Cancer. 2006 Mar;13(1):79-93. doi: 10.1677/erc.1.00988.
• [61] Characterization of arsenic-induced cytogenetic alterations in acute promyelocytic leukemia cell line, NB4. Med Oncol. 2012 Jun;29(2):1209-16. doi: 10.1007/s12032-011-9946-4. Epub 2011 May 5.
• [62] Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chem Biol Interact. 2010 Jul 30;186(2):127-34. doi: 10.1016/j.cbi.2010.04.027. Epub 2010 May 21.
• [63] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [64] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [65] Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environ Toxicol. 2018 Nov;33(11):1168-1181. doi: 10.1002/tox.22623. Epub 2018 Aug 27.
• [66] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [67] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [68] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [69] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [70] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [71] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [72] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [73] Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
• [74] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [75] Classification of heavy-metal toxicity by human DNA microarray analysis. Environ Sci Technol. 2007 May 15;41(10):3769-74.
• [76] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [77] Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
• [78] mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
• [79] Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
• [80] Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
• [81] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [82] Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
• [83] Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
• [84] Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
• [85] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
• [86] Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
• [87] Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.
• [88] Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling. Mutat Res. 2007 Jun 1;619(1-2):16-29. doi: 10.1016/j.mrfmmm.2006.12.007. Epub 2007 Feb 8.
• [89] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [90] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [91] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [92] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [93] Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
• [94] Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
• [95] Heat shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic trioxide-induced mitotic apoptosis. Toxicol Appl Pharmacol. 2009 Apr 15;236(2):231-8. doi: 10.1016/j.taap.2009.02.003. Epub 2009 Feb 12.
• [96] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [97] Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
• [98] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [99] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [100] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [101] Arsenic exposure, telomere length, and expression of telomere-related genes among Bangladeshi individuals. Environ Res. 2015 Jan;136:462-9. doi: 10.1016/j.envres.2014.09.040. Epub 2014 Nov 25.
• [102] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [103] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [104] Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. Mol Immunol. 2007 May;44(12):3222-33.
• [105] Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
• [106] The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. Toxicol Sci. 2009 Jan;107(1):40-55.
• [107] Bone marrow osteoblast damage by chemotherapeutic agents. PLoS One. 2012;7(2):e30758. doi: 10.1371/journal.pone.0030758. Epub 2012 Feb 17.
• [108] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [109] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [110] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [111] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [112] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [113] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [114] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [115] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [116] Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells. Anticancer Res. 2006 Sep-Oct;26(5A):3205-15.
• [117] Acetaminophen-induced proliferation of estrogen-responsive breast cancer cells is associated with increases in c-myc RNA expression and NF-kappaB activity. Toxicol Sci. 2002 Apr;66(2):233-43. doi: 10.1093/toxsci/66.2.233.
• [118] Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
• [119] Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
• [120] ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther. 2007 May;6(5):1579-87. doi: 10.1158/1535-7163.MCT-06-0814.
• [121] Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
• [122] Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
• [123] Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
• [124] Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. 2002 Nov 1;62(21):6006-10.
• [125] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [126] Retinoic acid can induce markers of endocrine transdifferentiation in pancreatic ductal adenocarcinoma: preliminary observations from an in vitro cell line model. J Clin Pathol. 2006 Jun;59(6):603-10. doi: 10.1136/jcp.2005.032003. Epub 2006 Feb 10.
• [127] Effects of metoclopramide on duodenal motility and flow events, glucose absorption, and incretin hormone release in response to intraduodenal glucose infusion. Am J Physiol Gastrointest Liver Physiol. 2010 Dec;299(6):G1326-33. doi: 10.1152/ajpgi.00476.2009. Epub 2010 Sep 9.
• [128] Glucagon secretion in primary endogenous hypertriglyceridemia before and after clofibrate treatment. Metabolism. 1975 Aug;24(8):901-14. doi: 10.1016/0026-0495(75)90081-5.
• [129] Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003 Aug;88(8):3829-34. doi: 10.1210/jc.2003-030199.
• [130] Combined contributions of over-secreted glucagon-like peptide 1 and suppressed insulin secretion to hyperglycemia induced by gatifloxacin in rats. Toxicol Appl Pharmacol. 2013 Feb 1;266(3):375-84. doi: 10.1016/j.taap.2012.11.015. Epub 2012 Nov 28.
• [131] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [132] Activation of intestinal olfactory receptor stimulates glucagon-like peptide-1 secretion in enteroendocrine cells and attenuates hyperglycemia in type 2 diabetic mice. Sci Rep. 2017 Oct 25;7(1):13978. doi: 10.1038/s41598-017-14086-5.
• [133] AZT-induced hypermethylation of human thymidine kinase gene in the absence of total DNA hypermethylation. FEBS Lett. 1996 Nov 4;396(2-3):323-6. doi: 10.1016/0014-5793(96)01124-6.
• [134] Fluorodeoxyuridine modulates cellular expression of the DNA base excision repair enzyme uracil-DNA glycosylase. Cancer Res. 2006 Sep 1;66(17):8829-37. doi: 10.1158/0008-5472.CAN-06-0540.
• [135] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [136] Delivery method, target gene structure, and growth properties of target cells impact mutagenic responses to reactive nitrogen and oxygen species. Chem Res Toxicol. 2012 Apr 16;25(4):873-83. doi: 10.1021/tx2004882. Epub 2012 Feb 21.
• [137] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [138] Development of an integrated assay in human TK6 cells to permit comprehensive genotoxicity analysis in vitro. Mutat Res Genet Toxicol Environ Mutagen. 2020 Jan;849:503129. doi: 10.1016/j.mrgentox.2019.503129. Epub 2019 Dec 27.
• [139] E2F1 downregulation by arsenic trioxide in lung adenocarcinoma. Int J Oncol. 2014 Nov;45(5):2033-43. doi: 10.3892/ijo.2014.2609. Epub 2014 Aug 19.
• [140] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [141] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [142] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [143] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [144] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [145] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [146] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [147] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [148] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
• [149] Increased organophosphate scavenging in a butyrylcholinesterase mutant. Chem Biol Interact. 2008 Sep 25;175(1-3):376-9. doi: 10.1016/j.cbi.2008.04.012. Epub 2008 Apr 22.
• [150] Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase. Arch Biochem Biophys. 2008 Oct 15;478(2):201-5.
• [151] Lichens of parmelioid clade as promising multitarget neuroprotective agents. Chem Res Toxicol. 2019 Jun 17;32(6):1165-1177.
• [152] Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7.
• [153] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [154] Response of the newborn to succinlycholine injection in homozygotic atypical mothers. Anesthesiology. 1975 Jul;43(1):115-6. doi: 10.1097/00000542-197507000-00028.
• [155] Cholinesterase inhibition by phenothiazine and nonphenothiazine antihistaminics: analysis of its postulated role in synergizing organophosphate toxicity. Toxicol Appl Pharmacol. 1975 Feb;31(2):179-90.
• [156] Qualitative defects of pseudocholinesterase activity. Anaesthesia. 1967 Jan;22(1):55-68.
• [157] G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem. 1993 Apr 15;268(11):8298-308.
• [158] Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
• [159] Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
• [160] Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
• [161] Effects of natural products and nutraceuticals on steroid hormone-regulated gene expression. Clin Chim Acta. 2001 Oct;312(1-2):213-9. doi: 10.1016/s0009-8981(01)00626-x.
• [162] EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24.
• [163] Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells. Prostate. 2007 Aug 1;67(11):1152-62. doi: 10.1002/pros.20585.
• [164] Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
• [165] An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer. 2003 Mar 24;88(6):822-7. doi: 10.1038/sj.bjc.6600817.
• [166] Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 1;70(14):1575-85. doi: 10.1002/pros.21193.
• [167] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [168] Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
• [169] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [170] Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
• [171] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [172] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [173] Monitoring of deiodinase deficiency based on transcriptomic responses in SH-SY5Y cells. Arch Toxicol. 2013 Jun;87(6):1103-13. doi: 10.1007/s00204-013-1018-4. Epub 2013 Feb 10.
• [174] Evaluation of early biomarkers of muscle anabolic response to testosterone. J Cachexia Sarcopenia Muscle. 2011 Mar;2(1):45-56. doi: 10.1007/s13539-011-0021-y. Epub 2011 Feb 26.
• [175] Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol. 2002 Jun;16(6):1243-56.
• [176] Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
• [177] Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
• [178] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [179] Ribavirin inhibits colorectal cancer growth by downregulating PRMT5 expression and H3R8me2s and H4R3me2s accumulation. Toxicol Appl Pharmacol. 2021 Mar 15;415:115450. doi: 10.1016/j.taap.2021.115450. Epub 2021 Feb 9.
• [180] Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci. 2009 Nov;100(11):2226-33. doi: 10.1111/j.1349-7006.2009.01306.x. Epub 2009 Aug 4.
• [181] Epinephrine facilitates the growth of T cell lymphoma by altering cell proliferation, apoptosis, and glucose metabolism. Chem Biol Interact. 2023 Jan 5;369:110278. doi: 10.1016/j.cbi.2022.110278. Epub 2022 Nov 22.
• [182] The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells. Mol Pharmacol. 2002 Nov;62(5):1027-35. doi: 10.1124/mol.62.5.1027.
• [183] Evaluation of a human iPSC-derived BBB model for repeated dose toxicity testing with cyclosporine A as model compound. Toxicol In Vitro. 2021 Jun;73:105112. doi: 10.1016/j.tiv.2021.105112. Epub 2021 Feb 22.
• [184] The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
• [185] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [186] Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer. 2010 Jun 29;103(1):52-60.
• [187] Inhibiting Heat Shock Proteins Can Potentiate the Cytotoxic Effect of Cannabidiol in Human Glioma Cells. Anticancer Res. 2015 Nov;35(11):5827-37.
• [188] Development and validation of the TGx-HDACi transcriptomic biomarker to detect histone deacetylase inhibitors in human TK6 cells. Arch Toxicol. 2021 May;95(5):1631-1645. doi: 10.1007/s00204-021-03014-2. Epub 2021 Mar 26.
• [189] Identification of novel activators of the metal responsive transcription factor (MTF-1) using a gene expression biomarker in a microarray compendium. Metallomics. 2020 Sep 23;12(9):1400-1415. doi: 10.1039/d0mt00071j.
• [190] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [191] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [192] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [193] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [194] Considering temozolomide as a novel potential treatment for esophageal cancer. Cancer. 2011 May 1;117(9):2004-16. doi: 10.1002/cncr.25687. Epub 2010 Nov 8.
• [195] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [196] Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J Biol Chem. 2002 Dec 13;277(50):48366-71. doi: 10.1074/jbc.M209074200. Epub 2002 Oct 9.
• [197] Riluzole induces AR degradation via endoplasmic reticulum stress pathway in androgen-dependent and castration-resistant prostate cancer cells. Prostate. 2019 Feb;79(2):140-150. doi: 10.1002/pros.23719. Epub 2018 Oct 2.
• [198] LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4179-E4188.
• [199] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [200] Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest New Drugs. 2007 Oct;25(5):491-7.
• [201] Differential expression of microRNAs and their predicted targets in renal cells exposed to amphotericin B and its complex with copper (II) ions. Toxicol Mech Methods. 2017 Sep;27(7):537-543. doi: 10.1080/15376516.2017.1333554. Epub 2017 Jun 8.
• [202] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [203] Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 2007 Jan;6(1):51-60. doi: 10.1158/1535-7163.MCT-06-0144. Epub 2007 Jan 11.
• [204] TGF-1 signaling protects retinal ganglion cells from oxidative stress via modulation of the HO-1/Nrf2 pathway. Chem Biol Interact. 2020 Nov 1;331:109249. doi: 10.1016/j.cbi.2020.109249. Epub 2020 Sep 24.
• [205] Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways. BMC Cancer. 2005 Jul 7;5:74. doi: 10.1186/1471-2407-5-74.
• [206] 2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo. Cancer Detect Prev. 2004;28(6):433-42. doi: 10.1016/j.cdp.2004.08.001.
• [207] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [208] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [209] Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells. Stem Cells. 2007 Mar;25(3):771-8. doi: 10.1634/stemcells.2006-0271. Epub 2006 Nov 30.
• [210] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [211] NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells. J Biol Chem. 2019 May 24;294(21):8543-8554. doi: 10.1074/jbc.RA118.006983. Epub 2019 Apr 2.
• [212] Role of phenytoin in wound healing: microarray analysis of early transcriptional responses in human dermal fibroblasts. Biochem Biophys Res Commun. 2004 Feb 13;314(3):661-6. doi: 10.1016/j.bbrc.2003.12.146.
• [213] Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
• [214] Chromium III histidinate exposure modulates gene expression in HaCaT human keratinocytes exposed to oxidative stress. Biol Trace Elem Res. 2010 Oct;137(1):23-39.
• [215] A dual role of p21waf1/cip1 gene in apoptosis of HEp-2 treated with cisplatin or methotrexate. Cancer Gene Ther. 2008 Sep;15(9):576-90. doi: 10.1038/cgt.2008.28. Epub 2008 May 16.
• [216] Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
• [217] Quercetin and Its Fermented Extract as a Potential Inhibitor of Bisphenol A-Exposed HT-29 Colon Cancer Cells' Viability. Int J Mol Sci. 2023 Mar 15;24(6):5604. doi: 10.3390/ijms24065604.
• [218] The Effect of GADD45a on Furazolidone-Induced S-Phase Cell-Cycle Arrest in Human Hepatoma G2 Cells. J Biochem Mol Toxicol. 2015 Oct;29(10):489-495. doi: 10.1002/jbt.21719. Epub 2015 Jun 11.
• [219] Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene. 2004 Jun 3;23(26):4614-23. doi: 10.1038/sj.onc.1207598.
• [220] S100P is selectively upregulated in tumor cell lines challenged with DNA cross-linking agents. Leuk Res. 2005 Oct;29(10):1181-90. doi: 10.1016/j.leukres.2005.03.012.
• [221] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [222] Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
• [223] Using a customized DNA microarray for expression profiling of the estrogen-responsive genes to evaluate estrogen activity among natural estrogens and industrial chemicals. Environ Health Perspect. 2004 May;112(7):773-81. doi: 10.1289/ehp.6753.
• [224] Extracellular ATP drives breast cancer cell migration and metastasis via S100A4 production by cancer cells and fibroblasts. Cancer Lett. 2018 Aug 28;430:1-10. doi: 10.1016/j.canlet.2018.04.043. Epub 2018 May 5.
• [225] 14-3-3 regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression. Oncotarget. 2016 Apr 5;7(14):17726-36. doi: 10.18632/oncotarget.7394.
• [226] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [227] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [228] Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis. J Cell Biochem. 2017 Apr;118(4):819-828. doi: 10.1002/jcb.25757. Epub 2016 Nov 28.
• [229] Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
• [230] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [231] Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain Res. 2006 Oct 20;1116(1):39-49.
• [232] Proteomic analysis of anti-cancer effects by paclitaxel treatment in cervical cancer cells. Gynecol Oncol. 2005 Jul;98(1):45-53. doi: 10.1016/j.ygyno.2005.04.010.
• [233] Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
• [234] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [235] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [236] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [237] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [238] Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res. 2006 Mar 1;66(5):2765-77.
• [239] Synergistic effects of arsenic trioxide combined with ascorbic acid in human osteosarcoma MG-63 cells: a systems biology analysis. Eur Rev Med Pharmacol Sci. 2014;18(24):3877-88.
• [240] Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711. doi: 10.1371/journal.pone.0036711. Epub 2012 May 4.
• [241] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [242] Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. Mutagenesis. 2005 Mar;20(2):139-46. doi: 10.1093/mutage/gei019. Epub 2005 Mar 22.
• [243] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [244] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [245] BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
• [246] Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
• [247] Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res. 2000 Mar;6(3):891-900.
• [248] Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res. 2005 Sep 1;65(17):7856-65. doi: 10.1158/0008-5472.CAN-05-1056.
• [249] Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.
• [250] Effect of menstrual cycle and hormonal treatment on ki-67 and bcl-2 expression and adenomyosis. Gynecol Endocrinol. 2005 Mar;20(3):127-31. doi: 10.1080/09513590400021086.
• [251] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [252] An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257.
• [253] Mitophagy inhibits proliferation by decreasing cyclooxygenase-2 (COX-2) in arsenic trioxide-treated HepG2 cells. Environ Toxicol Pharmacol. 2016 Jul;45:212-21.
• [254] Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chem Biol Interact. 2021 Nov 1;349:109652. doi: 10.1016/j.cbi.2021.109652. Epub 2021 Sep 11.
• [255] Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
• [256] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [257] High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res. 2009 Oct 1;15(19):6070-8.
• [258] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [259] Regulation of type III iodothyronine deiodinase expression in human cell lines. Endocrinology. 2006 Dec;147(12):5845-54. doi: 10.1210/en.2006-0590. Epub 2006 Aug 24.
• [260] MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma. Endocr Relat Cancer. 2016 Mar;23(3):135-46. doi: 10.1530/ERC-15-0162.
• [261] Screening the ToxCast Phase 1, Phase 2, and e1k Chemical Libraries for Inhibitors of Iodothyronine Deiodinases. Toxicol Sci. 2019 Apr 1;168(2):430-442. doi: 10.1093/toxsci/kfy302.
• [262] Disturbance of the Dlk1-Dio3 imprinted domain may underlie placental Dio3 suppression and extracellular thyroid hormone disturbance in placenta-derived JEG-3 cells following decabromodiphenyl ether (BDE209) exposure. Toxicology. 2021 Jun 30;458:152837. doi: 10.1016/j.tox.2021.152837. Epub 2021 Jun 21.
• [263] Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010 Sep;27(3):833-42. doi: 10.1007/s12032-009-9294-9. Epub 2009 Sep 10.
• [264] Neutrophil gelatinase-associated lipocalin production negatively correlates with HK-2 cell impairment: Evaluation of NGAL as a marker of toxicity in HK-2 cells. Toxicol In Vitro. 2017 Mar;39:52-57. doi: 10.1016/j.tiv.2016.11.012. Epub 2016 Nov 22.
• [265] Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
• [266] [Effects of Arsenic Trioxide on Cdc20 and Mad2 in Acute Myeloid Leukemia HL-60 Cell Line]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Jun;26(3):710-715. doi: 10.7534/j.issn.1009-2137.2018.03.013.
• [267] Gene expression profile induced by arsenic trioxide in chronic lymphocytic leukemia cells reveals a central role for heme oxygenase-1 in apoptosis and regulation of matrix metalloproteinase-9. Oncotarget. 2016 Dec 13;7(50):83359-83377.
• [268] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [269] Antidepressant drug sertraline modulates AMPK-MTOR signaling-mediated autophagy via targeting mitochondrial VDAC1 protein. Autophagy. 2021 Oct;17(10):2783-2799. doi: 10.1080/15548627.2020.1841953. Epub 2020 Nov 9.
• [270] Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells. Clin Lung Cancer. 2015 Sep;16(5):e55-66. doi: 10.1016/j.cllc.2015.03.006. Epub 2015 Apr 2.
• [271] MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
• [272] Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma. Br J Dermatol. 2019 Feb;180(2):346-356. doi: 10.1111/bjd.17333. Epub 2018 Nov 25.
• [273] Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8.
• [274] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [275] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [276] Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. Food Chem Toxicol. 2008 Jun;46(6):2042-53. doi: 10.1016/j.fct.2008.01.049. Epub 2008 Feb 7.
• [277] The retinoid anticancer signal: mechanisms of target gene regulation. Br J Cancer. 2005 Aug 8;93(3):310-8. doi: 10.1038/sj.bjc.6602700.
• [278] Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells. Mol Cancer Ther. 2003 Sep;2(9):893-900.
• [279] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [280] Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol. 2003 May;85(1):1-8. doi: 10.1016/s0960-0760(03)00142-0.
• [281] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [282] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [283] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [284] Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
• [285] Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells. Sci Rep. 2013 Oct 11;3:2899. doi: 10.1038/srep02899.
• [286] A high concentration of genistein down-regulates activin A, Smad3 and other TGF-beta pathway genes in human uterine leiomyoma cells. Exp Mol Med. 2012 Apr 30;44(4):281-92.
• [287] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [288] Epigenetic activation of O-linked -N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine. 2020 Apr;54:102678. doi: 10.1016/j.ebiom.2020.102678. Epub 2020 Apr 6.
• [289] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [290] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [291] Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis. 2010 Jun 2;9:56. doi: 10.1186/1476-511X-9-56.
• [292] Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
• [293] A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 2012 Jul;33(7):1421-9.
• [294] Transcriptional regulation of the homeobox gene NKX3.1 by all-trans retinoic acid in prostate cancer cells. J Cell Biochem. 2006 Dec 1;99(5):1409-19. doi: 10.1002/jcb.21020.
• [295] Curcumin downregulates homeobox gene NKX3.1 in prostate cancer cell LNCaP. Acta Pharmacol Sin. 2007 Mar;28(3):423-30. doi: 10.1111/j.1745-7254.2007.00501.x.
• [296] Effects of 9-cis retinoic acid on human homeobox gene NKX3.1 expression in prostate cancer cell line LNCaP. Asian J Androl. 2006 Jul;8(4):435-41. doi: 10.1111/j.1745-7262.2006.00171.x.
• [297] Identification of biomarkers and outcomes of endocrine disruption in human ovarian cortex using In Vitro Models. Toxicology. 2023 Feb;485:153425. doi: 10.1016/j.tox.2023.153425. Epub 2023 Jan 5.
• [298] A role for DNA methylation in regulating the growth suppressor PMEPA1 gene in prostate cancer. Epigenetics. 2007 Apr-Jun;2(2):100-9.
• [299] Expression profile analysis of human peripheral blood mononuclear cells in response to aspirin. Arch Immunol Ther Exp (Warsz). 2005 Mar-Apr;53(2):151-8.
• [300] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [301] Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. Toxicol Appl Pharmacol. 2010 Oct 15;248(2):111-21.
• [302] Characterisation of cisplatin-induced transcriptomics responses in primary mouse hepatocytes, HepG2 cells and mouse embryonic stem cells shows conservation of regulating transcription factor networks. Mutagenesis. 2014 Jan;29(1):17-26.
• [303] Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
• [304] Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicol In Vitro. 2009 Apr;23(3):486-99.
• [305] Gene expression signatures after ethanol exposure in differentiating embryoid bodies. Toxicol In Vitro. 2018 Feb;46:66-76.
• [306] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [307] Reproducible chemical-induced changes in gene expression profiles in human hepatoma HepaRG cells under various experimental conditions. Toxicol In Vitro. 2009 Apr;23(3):466-75. doi: 10.1016/j.tiv.2008.12.018. Epub 2008 Dec 30.
• [308] Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. doi: 10.1111/j.1349-7006.2006.00204.x.
• [309] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [310] Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
• [311] BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16;146(6):904-17.
• [312] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [313] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [314] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [315] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [316] Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet. 2010 Jun;199(2):110-20. doi: 10.1016/j.cancergencyto.2010.02.010.
• [317] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [318] An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
• [319] Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
• [320] Actinomycin D inhibits the expression of the cystine/glutamate transporter xCT via attenuation of CD133 synthesis in CD133(+) HCC. Chem Biol Interact. 2019 Aug 25;309:108713. doi: 10.1016/j.cbi.2019.06.026. Epub 2019 Jun 19.
• [321] Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
• [322] Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
• [323] G418-mediated ribosomal read-through of a nonsense mutation causing autosomal recessive proximal renal tubular acidosis. Am J Physiol Renal Physiol. 2008 Sep;295(3):F633-41. doi: 10.1152/ajprenal.00015.2008. Epub 2008 Jul 9.
• [324] Gene-specific differential DNA methylation and chronic arsenic exposure in an epigenome-wide association study of adults in Bangladesh. Environ Health Perspect. 2015 Jan;123(1):64-71. doi: 10.1289/ehp.1307884. Epub 2014 Oct 17.
• [325] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [326] Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009 Aug 21;138(4):645-659. doi: 10.1016/j.cell.2009.06.034. Epub 2009 Aug 13.
• [327] Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig. 2005 Oct;12(7):e55-67.
• [328] Folate deficiency in normal human fibroblasts leads to altered expression of genes primarily linked to cell signaling, the cytoskeleton and extracellular matrix. J Nutr Biochem. 2007 Aug;18(8):541-52. doi: 10.1016/j.jnutbio.2006.11.002. Epub 2007 Feb 22.
• [329] Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression. Environ Toxicol. 2018 Jun;33(6):659-669.
• [330] Fetal-sex dependent genomic responses in the circulating lymphocytes of arsenic-exposed pregnant women in New Hampshire. Reprod Toxicol. 2017 Oct;73:184-195. doi: 10.1016/j.reprotox.2017.07.023. Epub 2017 Aug 6.
• [331] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [332] Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. Br J Cancer. 2007 Jun 4;96(11):1675-83.
• [333] Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia. 2000 Feb;14(2):262-70. doi: 10.1038/sj.leu.2401650.
• [334] Folic acid enforces DNA methylation-mediated transcriptional silencing of PTEN, APC and RARbeta2 tumour suppressor genes in breast cancer. Biochem Biophys Res Commun. 2013 Jan 11;430(2):623-8. doi: 10.1016/j.bbrc.2012.11.103. Epub 2012 Dec 3.
• [335] The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int J Oncol. 2004 Aug;25(2):493-502.
• [336] Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006 Sep;8(9):758-71.
• [337] Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation. BMC Cancer. 2014 Apr 23;14:283.
• [338] Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
• [339] Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
• [340] Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia. J Cell Mol Med. 2018 Mar;22(3):1614-1626.
• [341] Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells. Toxicol Sci. 2018 Aug 1;164(2):477-488.
• [342] Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168.
• [343] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [344] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [345] Antiepileptic drugs are endocrine disruptors for the human fetal testis ex vivo. Toxicol Sci. 2023 Sep 28;195(2):169-183. doi: 10.1093/toxsci/kfad076.
• [346] Distinctive profiles of gene expression in the human nucleus accumbens associated with cocaine and heroin abuse. Neuropsychopharmacology. 2006 Oct;31(10):2304-12. doi: 10.1038/sj.npp.1301089. Epub 2006 May 3.
• [347] Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet. 2020 May;52(5):473-481. doi: 10.1038/s41588-020-0615-4. Epub 2020 May 4.
• [348] Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. Mol Endocrinol. 2008 Feb;22(2):287-303. doi: 10.1210/me.2007-0340. Epub 2007 Oct 25.
• [349] Bisphenol A and bisphenol S induce distinct transcriptional profiles in differentiating human primary preadipocytes. PLoS One. 2016 Sep 29;11(9):e0163318.
• [350] Impairment of hypoxia-induced HIF-1 signaling in keratinocytes and fibroblasts by sulfur mustard is counteracted by a selective PHD-2 inhibitor. Arch Toxicol. 2016 May;90(5):1141-50. doi: 10.1007/s00204-015-1549-y. Epub 2015 Jun 17.
• [351] Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene. 2005 Feb 3;24(6):980-91. doi: 10.1038/sj.onc.1208095.
• [352] Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3767-77.
• [353] Moving toward integrating gene expression profiling into high-throughput testing: a gene expression biomarker accurately predicts estrogen receptor alpha modulation in a microarray compendium. Toxicol Sci. 2016 May;151(1):88-103.
• [354] An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62.
• [355] Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.
• [356] Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
• [357] Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
• [358] Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
• [359] Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
• [360] HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.
• [361] Oral vitamin D rapidly attenuates inflammation from sunburn: an interventional study. J Invest Dermatol. 2017 Oct;137(10):2078-2086.
• [362] Cell death mechanisms of the anti-cancer drug etoposide on human cardiomyocytes isolated from pluripotent stem cells. Arch Toxicol. 2018 Apr;92(4):1507-1524.
• [363] The thioxotriazole copper(II) complex A0 induces endoplasmic reticulum stress and paraptotic death in human cancer cells. J Biol Chem. 2009 Sep 4;284(36):24306-19.
• [364] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [365] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [366] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [367] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [368] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [369] Study of low-density lipoprotein receptor regulation by oral (steroid) contraceptives: desogestrel, levonorgestrel and ethinyl estradiol in JEG-3 cell line and placental tissue. Contraception. 2007 Oct;76(4):297-305. doi: 10.1016/j.contraception.2007.06.011. Epub 2007 Sep 14.
• [370] Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression. J Biol Chem. 2020 Nov 20;295(47):15870-15882. doi: 10.1074/jbc.RA120.015623. Epub 2020 Sep 10.
• [371] Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
• [372] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [373] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [374] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [375] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [376] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [377] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [378] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [379] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [380] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [381] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [382] Insulin-like growth factors (IGF) I and II utilize different calcium signaling pathways in a primary human parathyroid cell culture model. World J Surg. 2006 Mar;30(3):333-45. doi: 10.1007/s00268-005-0339-8.
• [383] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [384] Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem. 2010 Nov;344(1-2):173-84. doi: 10.1007/s11010-010-0540-4. Epub 2010 Jul 25.
• [385] Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol. 2005 Aug 10;23(23):5334-46. doi: 10.1200/JCO.2005.03.723. Epub 2005 Jun 6.
• [386] DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab. 2006 May;290(5):E952-60. doi: 10.1152/ajpendo.00451.2005. Epub 2005 Dec 20.
• [387] Pleiotropic beta-agonist-promoted receptor conformations and signals independent of intrinsic activity. Am J Respir Cell Mol Biol. 2007 Feb;36(2):236-43. doi: 10.1165/rcmb.2006-0257OC. Epub 2006 Sep 15.
• [388] Development of 3D-QSAR models for predicting the activities of chemicals to stimulate muscle growth via (2)-adrenoceptor. Toxicol In Vitro. 2021 Dec;77:105251. doi: 10.1016/j.tiv.2021.105251. Epub 2021 Sep 30.
• [389] Beta2-adrenergic receptor polymorphisms in African American children with status asthmaticus. Pediatr Crit Care Med. 2006 Jan;7(1):15-8. doi: 10.1097/01.pcc.0000194010.63115.a2.
• [390] beta2-adrenergic receptor polymorphisms and salbutamol-stimulated energy expenditure. J Clin Endocrinol Metab. 2005 Apr;90(4):2301-7. doi: 10.1210/jc.2004-1356. Epub 2005 Feb 1.
• [391] Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome. Eur J Pharmacol. 1999 Dec 15;386(2-3):135-44. doi: 10.1016/s0014-2999(99)00749-9.
• [392] Myocardial ischaemia and ventricular arrhthymias precipitated by physiological concentrations of adrenaline in patients with coronary artery disease. Br Heart J. 1992 May;67(5):419-20. doi: 10.1136/hrt.67.5.419-b.
• [393] Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778.
• [394] Histamine augments beta2-adrenoceptor-induced cyclic AMP accumulation in human prostate cancer cells DU-145 independently of known histamine receptors. Biochem Pharmacol. 2007 Mar 15;73(6):814-23. doi: 10.1016/j.bcp.2006.11.022. Epub 2006 Dec 1.
• [395] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [396] Androgen receptor modulation following combination exposure to brominated flame-retardants. Sci Rep. 2018 Mar 19;8(1):4843. doi: 10.1038/s41598-018-23181-0.
• [397] In silico and in vitro assessment of androgen receptor antagonists. Comput Biol Chem. 2021 Jun;92:107490. doi: 10.1016/j.compbiolchem.2021.107490. Epub 2021 Apr 23.
• [398] Genistein disrupts glucocorticoid receptor signaling in human uterine endometrial Ishikawa cells. Environ Health Perspect. 2015 Jan;123(1):80-7. doi: 10.1289/ehp.1408437. Epub 2014 Aug 19.
• [399] Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):85-96.
• [400] Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 2011 Feb;123(3-5):140-50.
• [401] 4.8% sevoflurane induces activation of autophagy in human neuroblastoma SH-SY5Y cells by the AMPK/mTOR signaling pathway. Neurotoxicology. 2022 May;90:256-264. doi: 10.1016/j.neuro.2022.04.008. Epub 2022 Apr 23.
• [402] Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
• [403] Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann N Y Acad Sci. 2007 Jan;1095:35-44. doi: 10.1196/annals.1397.005.
• [404] Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004 Oct 19;502(3):169-83. doi: 10.1016/j.ejphar.2004.09.006.
• [405] Verapamil potentiates anti-glioblastoma efficacy of temozolomide by modulating apoptotic signaling. Toxicol In Vitro. 2018 Oct;52:306-313. doi: 10.1016/j.tiv.2018.07.001. Epub 2018 Jul 9.
• [406] Inhibition of caspase-dependent mitochondrial permeability transition protects airway epithelial cells against mustard-induced apoptosis. Apoptosis. 2006 Sep;11(9):1545-59. doi: 10.1007/s10495-006-8764-1.
• [407] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [408] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [409] Regulation of GCDFP-15 expression in human mammary cancer cells. Int J Mol Med. 1999 Aug;4(2):135-40. doi: 10.3892/ijmm.4.2.135.
• [410] Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein. Mol Cell Proteomics. 2011 Jan;10(1):M110.002170.
• [411] Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
• [412] Manganese superoxide dismutase induces migration and invasion of tongue squamous cell carcinoma via H2O2-dependent Snail signaling. Free Radic Biol Med. 2012 Jul 1;53(1):44-50. doi: 10.1016/j.freeradbiomed.2012.04.031. Epub 2012 May 9.
• [413] Nitric oxide causes anoikis through attenuation of E-cadherin and activation of caspase-3 in human gastric carcinoma AZ-521 cells infected with Mycoplasma hyorhinis. J Vet Med Sci. 2010 Jul;72(7):869-74.
• [414] Induced differentiation in HT29, a human colon adenocarcinoma cell line. J Cell Sci. 1999 Aug;112 ( Pt 16):2657-66. doi: 10.1242/jcs.112.16.2657.
• [415] Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
• [416] Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells. Biochem Biophys Res Commun. 2009 Mar 13;380(3):614-9. doi: 10.1016/j.bbrc.2009.01.134. Epub 2009 Jan 27.
• [417] Regulation of epithelial cell morphology and functions approaching to more in vivo-like by modifying polyethylene glycol on polysulfone membranes. PLoS One. 2012;7(4):e36110.
• [418] Pyrroloquinoline quinine ameliorates doxorubicin-induced autophagy-dependent apoptosis via lysosomal-mitochondrial axis in vascular endothelial cells. Toxicology. 2019 Sep 1;425:152238. doi: 10.1016/j.tox.2019.152238. Epub 2019 Jun 18.
• [419] Nicotine induces apoptosis through exacerbation of blocked alveolar macrophage autophagic degradation in silicosis. Toxicol Lett. 2020 Nov 1;334:94-101. doi: 10.1016/j.toxlet.2020.09.019. Epub 2020 Sep 30.
• [420] ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res. 2012 Apr 1;18(7):1979-91. doi: 10.1158/1078-0432.CCR-11-2113. Epub 2012 Feb 20.
• [421] Synthesis and antitumor evaluation of nitrovinyl biphenyls: anticancer agents based on allocolchicines. ChemMedChem. 2011 May 2;6(5):859-68. doi: 10.1002/cmdc.201100019. Epub 2011 Apr 6.
• [422] Selenium is critical for cancer-signaling gene expression but not cell proliferation in human colon Caco-2 cells. Biofactors. 2007;31(3-4):155-64. doi: 10.1002/biof.5520310302.
• [423] Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells. Oncol Rep. 2016 Sep;36(3):1233-42. doi: 10.3892/or.2016.4944. Epub 2016 Jul 15.
• [424] Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83.
• [425] Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Cancers (Basel). 2020 Sep 27;12(10):2774. doi: 10.3390/cancers12102774.
• [426] CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014 Jul;5(7-8):261-72. doi: 10.18632/genesandcancer.24.
• [427] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [428] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [429] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [430] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [431] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [432] The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 2001 Feb 1;20(5):645-53. doi: 10.1038/sj.onc.1204123.
• [433] Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast. 2018 Oct;41:34-41. doi: 10.1016/j.breast.2018.06.009. Epub 2018 Jun 22.
• [434] Cross-talk between non-genomic and genomic signalling pathways--distinct effect profiles of environmental estrogens. Toxicol Appl Pharmacol. 2010 Jun 1;245(2):160-70. doi: 10.1016/j.taap.2010.02.015. Epub 2010 Mar 4.
• [435] Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
• [436] Resveratrol attenuates senescence of adipose-derived mesenchymal stem cells and restores their paracrine effects on promoting insulin secretion of INS-1 cells through Pim-1. Eur Rev Med Pharmacol Sci. 2016;20(6):1203-13.
• [437] Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001 Sep;298(3):976-85.
• [438] All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br J Haematol. 2010 Jul;150(2):158-69. doi: 10.1111/j.1365-2141.2010.08209.x. Epub 2010 May 9.
• [439] A two-hybrid yeast assay to quantify the effects of xenobiotics on retinoid X receptor-mediated gene expression. Toxicol Lett. 2008 Feb 15;176(3):198-206. doi: 10.1016/j.toxlet.2007.11.006. Epub 2007 Dec 3.
• [440] Transient receptor potential vanilloid-1 signaling as a regulator of human sebocyte biology. J Invest Dermatol. 2009 Feb;129(2):329-39. doi: 10.1038/jid.2008.258. Epub 2008 Sep 4.
• [441] Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor , , subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11.
• [442] Photoaffinity labeling of human retinoid X receptor beta (RXRbeta) with 9-cis-retinoic acid: identification of phytanic acid, docosahexaenoic acid, and lithocholic acid as ligands for RXRbeta. Biochemistry. 2002 Apr 16;41(15):4883-90. doi: 10.1021/bi0121151.
• [443] Gene induction and apoptosis in human hepatocellular carci-noma cells SMMC-7721 exposed to 5-aza-2'-deoxycytidine. Chin Med J (Engl). 2007 Sep 20;120(18):1626-31.
• [444] Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
• [445] Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
• [446] Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
• [447] The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
• [448] Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
• [449] Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
• [450] Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
• [451] Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
• [452] Morphological and molecular course of mitochondrial pathology in cultured human cells exposed long-term to Zidovudine. Environ Mol Mutagen. 2007 Apr-May;48(3-4):179-89. doi: 10.1002/em.20245.
• [453] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [454] Astaxanthin protects mesenchymal stem cells from oxidative stress by direct scavenging of free radicals and modulation of cell signaling. Chem Biol Interact. 2021 Jan 5;333:109324. doi: 10.1016/j.cbi.2020.109324. Epub 2020 Nov 17.
• [455] Comparative effects of retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and expression of phosphatase and tensin homologue tumour suppressor gene in breast cancer cells. Br J Nutr. 2012 Mar;107(6):781-90. doi: 10.1017/S0007114511003631. Epub 2011 Aug 1.
• [456] Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway. Cancer Cell Int. 2013 Mar 13;13(1):25. doi: 10.1186/1475-2867-13-25.
• [457] Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. Chin Med J (Engl). 2009 Jun 5;122(11):1260-6.
• [458] Arsenic exposure in utero exacerbates skin cancer response in adulthood with contemporaneous distortion of tumor stem cell dynamics. Cancer Res. 2008 Oct 15;68(20):8278-85. doi: 10.1158/0008-5472.CAN-08-2099.
• [459] Comparison of transcriptome expression alterations by chronic exposure to low-dose bisphenol A in different subtypes of breast cancer cells. Toxicol Appl Pharmacol. 2019 Dec 15;385:114814. doi: 10.1016/j.taap.2019.114814. Epub 2019 Nov 9.
• [460] ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis. Blood. 2004 Jan 1;103(1):194-207.
• [461] Transcriptomic analysis of human primary bronchial epithelial cells after chloropicrin treatment. Chem Res Toxicol. 2015 Oct 19;28(10):1926-35.
• [462] Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
• [463] Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
• [464] Ornithine decarboxylase antizyme upregulates DNA-dependent protein kinase and enhances the nonhomologous end-joining repair of DNA double-strand breaks in human oral cancer cells. Biochemistry. 2007 Aug 7;46(31):8920-32. doi: 10.1021/bi7000328. Epub 2007 Jul 14.
• [465] Selective nonsteroidal anti-inflammatory drugs induce thymosin beta-4 and alter actin cytoskeletal organization in human colorectal cancer cells. J Pharmacol Exp Ther. 2004 Dec;311(3):885-91. doi: 10.1124/jpet.104.070664. Epub 2004 Aug 3.
• [466] 5-Fluorouracil: identification of novel downstream mediators of tumour response. Anticancer Res. 2004 Mar-Apr;24(2A):417-23.
• [467] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [468] Effects of gonadotrophin-releasing hormone agonists on apoptosis of granulosa cells. Ann N Y Acad Sci. 2005 May;1042:531-7. doi: 10.1196/annals.1338.065.
• [469] Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
• [470] Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
• [471] Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005 Feb 10;24(7):1231-43. doi: 10.1038/sj.onc.1208290.
• [472] Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
• [473] Evaluation of gene expression changes in human primary lung epithelial cells following 24-hr exposures to inorganic arsenic and its methylated metabolites and to arsenic trioxide. Environ Mol Mutagen. 2015 Jun;56(5):477-90. doi: 10.1002/em.21937. Epub 2015 Apr 14.
• [474] A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women. Thromb Res. 2012 Jul;130(1):45-51. doi: 10.1016/j.thromres.2011.12.009. Epub 2012 Jan 2.
• [475] Ultradian cortisol pulsatility encodes a distinct, biologically important signal. PLoS One. 2011 Jan 18;6(1):e15766.
• [476] Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. Oncol Rep. 2008 Jun;19(6):1627-34.
• [477] Low-dose Bisphenol A exposure alters the functionality and cellular environment in a human cardiomyocyte model. Environ Pollut. 2023 Oct 15;335:122359. doi: 10.1016/j.envpol.2023.122359. Epub 2023 Aug 9.
• [478] Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer. Cancer Res. 2005 Aug 1;65(15):6789-800. doi: 10.1158/0008-5472.CAN-04-2684.
• [479] Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
• [480] Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
• [481] Convergent transcriptional profiles induced by endogenous estrogen and distinct xenoestrogens in breast cancer cells. Carcinogenesis. 2006 Aug;27(8):1567-78.
• [482] In vitro aromatic bioactivation of the weak estrogen E(2)alpha and genesis of DNA adducts. Steroids. 2005 Mar;70(3):161-72. doi: 10.1016/j.steroids.2004.11.004.
• [483] Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
• [484] Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
• [485] Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020 Feb;62:104669. doi: 10.1016/j.tiv.2019.104669. Epub 2019 Oct 16.
• [486] Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 2008 May 1;68(9):3161-8. doi: 10.1158/0008-5472.CAN-07-6381.
• [487] Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
• [488] Comparison of quantitation methods in proteomics to define relevant toxicological information on AhR activation of HepG2 cells by BaP. Toxicology. 2021 Jan 30;448:152652. doi: 10.1016/j.tox.2020.152652. Epub 2020 Dec 2.
• [489] Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem. 2010 Dec 15;111(6):1546-55. doi: 10.1002/jcb.22886.
• [490] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [491] High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2058-63.
• [492] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [493] Pleiotropic combinatorial transcriptomes of human breast cancer cells exposed to mixtures of dietary phytoestrogens. Food Chem Toxicol. 2009 Apr;47(4):787-95.
• [494] Arsenic induces functional re-expression of estrogen receptor by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One. 2012;7(4):e35957. doi: 10.1371/journal.pone.0035957. Epub 2012 Apr 27.
• [495] Hypomethylation mediated by decreased DNMTs involves in the activation of proto-oncogene MPL in TK6 cells treated with hydroquinone. Toxicol Lett. 2012 Mar 25;209(3):239-45. doi: 10.1016/j.toxlet.2011.12.020. Epub 2012 Jan 8.
• [496] Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
• [497] Folate deficiency induces cell-specific changes in the steady-state transcript levels of genes involved in folate metabolism and 1-carbon transfer reactions in human colonic epithelial cells. J Nutr. 2007 Mar;137(3):607-13. doi: 10.1093/jn/137.3.607.
• [498] BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis. 2009 Apr;30(4):662-70. doi: 10.1093/carcin/bgp042. Epub 2009 Feb 12.
• [499] Estrogen down regulates COMT transcription via promoter DNA methylation in human breast cancer cells. Toxicol Appl Pharmacol. 2019 Mar 15;367:12-22.
• [500] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [501] Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
• [502] Epigenetic changes in individuals with arsenicosis. Chem Res Toxicol. 2011 Feb 18;24(2):165-7. doi: 10.1021/tx1004419. Epub 2011 Feb 4.
• [503] Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell. 2004 Mar;15(3):1262-72. doi: 10.1091/mbc.e03-06-0360. Epub 2003 Dec 29.
• [504] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [505] [Differential proteomic expression in human liver cells stimulated by hydroquinone]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2006 Nov;24(11):658-61.
• [506] Protein kinase C inhibitors alter neurotensin receptor binding and function in prostate cancer PC3 cells. Regul Pept. 2008 Apr 10;147(1-3):96-109. doi: 10.1016/j.regpep.2008.01.009. Epub 2008 Feb 11.
• [507] The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
• [508] Effects of progesterone treatment on expression of genes involved in uterine quiescence. Reprod Sci. 2011 Aug;18(8):781-97.